Ekso Bionics (EKSO) Stock On An Uptick

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) witnessed a notable surge in its stock value during the preceding trading session, experiencing a remarkable 15.00% ascent to settle at $2.99. The positive trajectory of Ekso Bionics stock closely followed the unveiling of a groundbreaking software solution.

In a recent announcement, Ekso Bionics (EKSO) revealed the introduction of GaitCoach, a cutting-edge gait therapy software tailored for EksoNR. GaitCoach stands as a comprehensive solution designed to support a diverse range of patients utilizing EksoNR. This innovative software aims to streamline the incorporation of robotics, fostering increased user confidence in technology.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

It provides impactful, dynamic feedback and serves as an additional clinical perspective, offering specific guidance. EKSO anticipates that GaitCoach will mitigate training requirements, enhance utilization, and make the device more intuitive for both patients and physical therapists. This new software replaces SmartAssist, the previously utilized software introduced in 2016 and optimized in 2019 alongside the launch of EksoNR.

Through meticulous attention to the feedback from physical therapists, clinicians, and patients, Ekso Bionics has elevated the EksoNR experience with GaitCoach, a solution meticulously crafted to advance patient rehabilitation. GaitCoach facilitates the customization of patient sessions, aligning them more closely with individual deficits and goals, thereby enabling therapists to deliver more efficient treatment.

The collaborative efforts of Ekso Bionics’ engineering and clinical teams, engaged in regular communication with frequent EksoNR users throughout the design process, underscore their dedication to meeting user needs. Feedback from experienced users of EksoNR following the introduction of GaitCoach has been overwhelmingly positive:

  • 96% found GaitCoach software to be very or extremely intuitive.
  • 93% acknowledged the value of guidance from GaitCoach, deeming it instrumental in making EksoNR more user-friendly.
  • 93% expressed belief in the utility of EksoNR with GaitCoach for new or less experienced therapists at their clinic.
  • 93% believed that the focused guidance provided by GaitCoach would contribute to achieving their clinical goals.
  • 79% anticipated that GaitCoach would facilitate easier patient progression.

The program is presently only accessible in the United States, which is notable. Ekso Bionics’ dedication to developing rehabilitative technologies and enhancing patient care globally is demonstrated by this strategic launch.

Most Popular